145 related articles for article (PubMed ID: 35676852)
1. Short-term Neuropsychiatric and Body Weight Changes in Patients Switching From EVG/Cobi/FTC/TAF to BIC/FTC/TAF (PreEC/RIS69).
Tiraboschi J; Prieto P; Saumoy M; Silva A; Imaz A; Scevola S; Fernandez G; Navarro A; Piatti C; Podzamczer D
Curr HIV Res; 2022; 20(3):251-254. PubMed ID: 35676852
[TBL] [Abstract][Full Text] [Related]
2. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S
BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984
[TBL] [Abstract][Full Text] [Related]
3. Randomized Trial Evaluating the Neurotoxicity of Dolutegravir/Abacavir/Lamivudine and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: GESIDA 9016.
Perez Valero I; Cabello A; Ryan P; De La Fuente-Moral S; Santos I; Vivancos MJ; Gonzalez A; Gorgolas M; Cuevas G; Diaz De Santiago A; Cano J; Rua G; Yllescas M; González García JJ
Open Forum Infect Dis; 2020 Dec; 7(12):ofaa482. PubMed ID: 33335931
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
Imaz A; Podzamczer D
Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
[TBL] [Abstract][Full Text] [Related]
5. EVG/COBI/FTC/TAF Bioequivalence Comparing Whole Tablets with Tablets Dissolved in Tap Water.
Andrade A; Fuchs EJ; Marzinke MA; Abdul Massih S; Breakey J; Beselman S; McNicholl I; Hendrix CW
AIDS Res Hum Retroviruses; 2023 Jan; 39(1):38-43. PubMed ID: 36301928
[TBL] [Abstract][Full Text] [Related]
6. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
[TBL] [Abstract][Full Text] [Related]
7. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Andreatta K; Willkom M; Martin R; Chang S; Wei L; Liu H; Liu YP; Graham H; Quirk E; Martin H; White KL
J Antimicrob Chemother; 2019 Dec; 74(12):3555-3564. PubMed ID: 31430369
[TBL] [Abstract][Full Text] [Related]
8. Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens.
Priest J; Germain G; Laliberté F; Duh MS; Mahendran M; Fakih I; Oglesby A
Infect Dis Ther; 2023 Aug; 12(8):2117-2133. PubMed ID: 37552426
[TBL] [Abstract][Full Text] [Related]
9. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Haaland RE; Martin A; Livermont T; Fountain J; Dinh C; Holder A; Lupo LD; Hall L; Conway-Washington C; Kelley CF
J Acquir Immune Defic Syndr; 2019 Nov; 82(3):252-256. PubMed ID: 31335590
[TBL] [Abstract][Full Text] [Related]
10. Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice.
Hoffmann C; Schewe K; Fenske S; Buhk T; Sabranski M; Adam A; Hansen S; Stellbrink HJ
Antivir Ther; 2020; 25(2):83-90. PubMed ID: 32235038
[TBL] [Abstract][Full Text] [Related]
11. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in the Treatment of HIV-Infected Patients: Experience with the First 100 Patients from Qatar.
Al Soub H; Al-Khal ALM; Alsoub D; Awouda W
Can J Infect Dis Med Microbiol; 2020; 2020():1597839. PubMed ID: 32849932
[TBL] [Abstract][Full Text] [Related]
12. Reasons, safety and efficacy analysis for conversion of HAART to TAF/FTC/BIC among HIV-infected patients.
Xiao J; Gao G; Ding Y; Li J; Gao C; Xu Q; Wu L; Liang H; Ni L; Wang F; Duan Y; Yang D; Zhao H
Chin Med J (Engl); 2023 Dec; 136(24):2931-2937. PubMed ID: 38032036
[TBL] [Abstract][Full Text] [Related]
13. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Sax PE; DeJesus E; Mills A; Zolopa A; Cohen C; Wohl D; Gallant JE; Liu HC; Zhong L; Yale K; White K; Kearney BP; Szwarcberg J; Quirk E; Cheng AK;
Lancet; 2012 Jun; 379(9835):2439-2448. PubMed ID: 22748591
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy, safety, and subjective experience based on ePRO in HIV-infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China.
Kong L; Xie X; Fu Y; Gan L; Yang X; Ma S; Long H
Immun Inflamm Dis; 2023 Aug; 11(8):e974. PubMed ID: 37647435
[TBL] [Abstract][Full Text] [Related]
15. Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study.
Emond B; Rossi C; Côté-Sergent A; Dunn K; Lefebvre P; Lafeuille MH; Donga P
J Health Econ Outcomes Res; 2021 Jun; 8(1):88-98. PubMed ID: 34179212
[No Abstract] [Full Text] [Related]
16. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
[TBL] [Abstract][Full Text] [Related]
17. Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.
Rocabert A; Borjabad B; Berrocal L; Blanch J; Inciarte A; Chivite I; Gonzalez-Cordon A; Torres B; Ambrosioni J; Martinez-Rebollar M; Laguno M; De La Mora L; Foncillas A; Sempere A; Rodriguez A; Solbes E; Llobet R; Miro JM; Mallolas J; Blanco JL; De Lazzari E; Martinez E
J Antimicrob Chemother; 2023 Dec; 78(12):2961-2967. PubMed ID: 37875023
[TBL] [Abstract][Full Text] [Related]
18. Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real-life experience from a French cohort (2019-2023).
Frange P; Veber F; Burgard M; Blanche S; Avettand-Fenoel V
HIV Med; 2024 Feb; 25(2):299-305. PubMed ID: 37807595
[TBL] [Abstract][Full Text] [Related]
19. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
[TBL] [Abstract][Full Text] [Related]
20. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
